
EBGLYSS Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis The positive CHMP opinion is now being reviewed by the European Commission (EC). The approval of this biologic in the European…












